Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Histotripsy 2.0 available for liver and breast cancer clinical trials in HK
Asia’s first histotripsy 2.0 system, introduced at the Chinese University Hong Kong (CUHK) recently, will be used in clinical trials to treat liver cancer patients from early 2025. The novel focal therapy will also be evaluated in patients with early-stage breast cancer.
Histotripsy 2.0 available for liver and breast cancer clinical trials in HK
05 Dec 2024
Motherhood among breast cancer survivors: Studies provide reassuring evidence on breastfeeding
For new mothers who have undergone breast cancer treatment, including those who harbour the BRCA gene mutation, breastfeeding appears to be a safe and viable option, posing no increased risk of recurrence or development of new breast cancers, according to new research.
Motherhood among breast cancer survivors: Studies provide reassuring evidence on breastfeeding
03 Dec 2024
Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).
Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
01 Dec 2024
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.